{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF&page=7",
    "query": {
      "intervention": "CSF",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 2030,
    "total_pages": 203,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CSF&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T08:34:49.554Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00600795",
      "title": "Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Normal Pressure Hydrocephalus"
      ],
      "interventions": [
        {
          "name": "CSF collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2008-01",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600795"
    },
    {
      "nct_id": "NCT00186888",
      "title": "Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Retinoblastoma",
        "Retinal Neoplasm"
      ],
      "interventions": [
        {
          "name": "Enucleation",
          "type": "PROCEDURE"
        },
        {
          "name": "Vincristine, Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Focal Therapies",
          "type": "PROCEDURE"
        },
        {
          "name": "External Beam Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Vincristine and Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Vincristine + Carboplatin + Etoposide",
          "type": "DRUG"
        },
        {
          "name": "vincristine, cyclophosphamide, and doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine, Carboplatin and Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Periocular carboplatin",
          "type": "PROCEDURE"
        },
        {
          "name": "G-CSF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 107,
      "start_date": "2005-04-07",
      "completion_date": "2024-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186888"
    },
    {
      "nct_id": "NCT00462605",
      "title": "MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2007-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-07-18",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00462605"
    },
    {
      "nct_id": "NCT02834741",
      "title": "Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NYX-2925",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptinyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-07",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834741"
    },
    {
      "nct_id": "NCT00810329",
      "title": "Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Fatigue Syndrome",
        "Fibromyalgia",
        "Gulf War Illness",
        "Multiple Chemical Sensitivity",
        "Interstitial Cystitis",
        "Irritable Bowel Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": "2007-07",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2014-02-25",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00810329"
    },
    {
      "nct_id": "NCT06964737",
      "title": "Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Malignant Glioma",
        "Recurrent WHO Grade 3 Glioma",
        "Recurrent WHO Grade 4 Glioma",
        "WHO Grade 2 Glioma",
        "WHO Grade 3 Glioma",
        "WHO Grade 4 Glioma"
      ],
      "interventions": [
        {
          "name": "Anti-GARP Chimeric Antigen Receptor-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-05-21",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06964737"
    },
    {
      "nct_id": "NCT00003183",
      "title": "Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hope Cancer Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 64,
      "start_date": "1997-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003183"
    },
    {
      "nct_id": "NCT01390402",
      "title": "Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "NK cell infusion:",
          "type": "PROCEDURE"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic related Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 6,
      "start_date": "2012-01",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01390402"
    },
    {
      "nct_id": "NCT00003541",
      "title": "Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CHOP regimen",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1998-06",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003541"
    },
    {
      "nct_id": "NCT00003927",
      "title": "Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 15,
      "start_date": "1999-05-18",
      "completion_date": "2023-03-21",
      "has_results": false,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-10-25T08:34:49.554Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003927"
    }
  ]
}